Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Sodium oxybate→

Sodium Oxybate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
502-85-2
PubChem CID
23663870
Molecular formula
C4H7NaO3
Molecular weight
126.09 g/mol
Drug class
Gamma-hydroxybutyrate (GHB/oxybate)central nervous system depressant
Mechanism of action
Acts through GHB and GABA-B receptor pathways. The precise mechanism by which sodium oxybate improves symptoms of narcolepsy is not fully understood; it affects sleep architecture and may consolidate nocturnal sleep, with downstream effects on cataplexy and excessive daytime sleepiness.
Indications / reported uses
  • Treatment of cataplexy in narcolepsy
  • Treatment of excessive daytime sleepiness in narcolepsy, including in paediatric patients where the formulation and local authorisation permit

Identification source: PubChem record (CID 23663870). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Sodium Oxybate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Sodium Oxybate Permitted Daily Exposure (PDE) report (the Sodium Oxybate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Sodium Oxybate Occupational Exposure Limit (OEL) report (the Sodium Oxybate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.